Humacyte (NASDAQ:HUMAW) Trading 6.9% Higher – Should You Buy?

Humacyte, Inc. (NASDAQ:HUMAWGet Free Report) shot up 6.9% on Friday . The company traded as high as $1.84 and last traded at $1.69. 10,292 shares changed hands during trading, a decline of 64% from the average session volume of 28,922 shares. The stock had previously closed at $1.58.

Humacyte Stock Up 6.9 %

The stock has a fifty day moving average price of $1.84 and a 200-day moving average price of $1.96.

About Humacyte

(Get Free Report)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

Featured Articles

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.